Merck's Cladribine and Multiple Sclerosis
From FierceBiotech:
Merck KGaA pulls ahead in hot oral MS drug race
By John Carroll
September 11, 2009 — 8:22am ET
Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential as a new therapy for multiple sclerosis. Patients taking a short course of the therapy were more likely to go two years without seeing the disease flare up, and that could prove crucial for the developer as it prepares to make its case that cladribine should be neurologists' preferred choice among a slate of experimental oral MS therapies.
Read the full article
Merck KGaA pulls ahead in hot oral MS drug race
By John Carroll
September 11, 2009 — 8:22am ET
Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential as a new therapy for multiple sclerosis. Patients taking a short course of the therapy were more likely to go two years without seeing the disease flare up, and that could prove crucial for the developer as it prepares to make its case that cladribine should be neurologists' preferred choice among a slate of experimental oral MS therapies.
Read the full article
Labels: Cladribine, FTY720, Merck, MS, multiple sclerosis, Novartis
posted by Anthony Risser at 5:34 PM
1 Comments:
MS Views and News is dedicated to the global collection and distribution of current information concerning Multiple Sclerosis. In collaboration with other organizations, MS Views and News uses state-of-the-art communication channels to provide information for those affected by, or interested in MS.
Visit: http://wwwmsviewsandrelatednews.blogspot.com- and then register at: http://www.msviewsandnews.org for our weekly MS e-newsletter
On facebook: Become a Fan - http://www.facebook.com/msviewsandnews
Thank you
Post a Comment
<< Home